Prevalence of HPV 16/18 genotypes and histopathologic follow-up outcomes in women with negative cytology and positive high-risk HPV test results

Management of human papillomavirus (HPV)-positive/cytology-negative patients has represented a special challenge ever since the introduction in 2003 of routine cytology and HPV cotesting of women 30 years and older. Since the U.S. Food and Drug Administration’s approval in 2009 of an HPV 16/18 genotyping test, guidelines have included an HPV 16/18 genotyping triage option for identifying high-risk HPV-positive/cytology-negative patients who would benefit from immediate colposcopic referral.